Navitoclax
Navitoclax is a BCL-XL/BCL-2 inhibitor that is being investigated to treat myelofibrosis.
Type of Molecule
Small MoleculeTarget
BCL-XL/BCL-2Product Type
New Indication| Potential Indication | Region | Phase (1, 2, 3, Submitted) |
|---|---|---|
| Myelofibrosis | n/a |
Phase 3
|